Advertisement

Dengue Vaccine Effective in Children in Endemic Regions — Physician’s First Watch

Medical News |
July 11, 2014

Dengue Vaccine Effective in Children in Endemic Regions

By Kelly Young

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

A vaccine candidate against the dengue virus showed efficacy in children in Asia, according to a phase-III trial published in the Lancet.

Over 10,000 children (aged 2 to 14 years) were randomized to receive recombinant, chimeric, live attenuated tetravalent dengue vaccine (three doses 6 months apart) or placebo.

During 25 months' surveillance, the vaccine was 56.5% effective. The vaccine was not effective against serotype 2. Efficacy was lower in younger than in older children, "which is of concern," a commentator writes, since younger children are at higher risk.

She concludes: "For the moment, [this] vaccine is the best we have. However, with a 56% efficacy this vaccine will never be a single solution. Continued support for the development of other novel strategies, including drugs, improved case management, insecticides, and new approaches to vector control, is needed before effective dengue control becomes a credible prospect."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement